Naoya Yamazaki
A5001893646- Melanoma and MAPK Pathways
- Cutaneous Melanoma Detection and Management
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Nonmelanoma Skin Cancer Studies
- Colorectal Cancer Treatments and Studies
- Cancer and Skin Lesions
- Immunotherapy and Immune Responses
- Cutaneous lymphoproliferative disorders research
- Cancer Genomics and Diagnostics
- Vascular Tumors and Angiosarcomas
- HER2/EGFR in Cancer Research
- Sarcoma Diagnosis and Treatment
- Chemotherapy-related skin toxicity
- Lung Cancer Treatments and Mutations
- Ear and Head Tumors
- Hedgehog Signaling Pathway Studies
- Colorectal and Anal Carcinomas
- Cancer Diagnosis and Treatment
- Bioinformatics and Genomic Networks
- Cardiac tumors and thrombi
- Cancer Treatment and Pharmacology
- Polyomavirus and related diseases
- Monoclonal and Polyclonal Antibodies Research
- Radiomics and Machine Learning in Medical Imaging
National Cancer Center Hospital East
2012-2024
Tokyo National Hospital
2015-2024
National Cancer Center
2014-2023
Osaka Metropolitan University
2023
Weatherford College
2020-2022
Check Point (Israel)
2022
Yokohama City University
2019
National Defense Medical College
2019
University of Tsukuba
2008-2013
Shinshu University
2002-2008
Nivolumab and ipilimumab are immune checkpoint inhibitors that have been approved for the treatment of advanced melanoma. In United States, has also as adjuvant therapy melanoma on basis recurrence-free overall survival rates were higher than those with placebo in a phase 3 trial. We wanted to determine efficacy nivolumab versus patients resected this randomized, double-blind, trial, we randomly assigned 906 (≥15 years age) who undergoing complete resection stage IIIB, IIIC, or IV receive an...
Recent studies have demonstrated the usefulness of convolutional neural networks (CNNs) to classify images melanoma, with accuracies comparable those achieved by dermatologists. However, performance a CNN trained only clinical pigmented skin lesion in image classification task, competition dermatologists, has not been reported date. In this study, we extracted 5846 lesions from 3551 patients. Pigmented included malignant tumors (malignant melanoma and basal cell carcinoma) benign (nevus,...
Poroma is a benign skin tumor exhibiting terminal sweat gland duct differentiation. The present study aimed to explore the potential role of gene fusions in tumorigenesis poromas. RNA sequencing and reverse transcription PCR identified highly recurrent YAP1-MAML2 YAP1-NUTM1 poromas (92/104 lesions, 88.5%) their rare malignant counterpart, porocarcinomas (7/11 63.6%). A WWTR1-NUTM1 fusion was single lesion poroma. Fluorescence situ hybridization confirmed genomic rearrangements involving...
Combination treatment with BRAF and MEK inhibitors has demonstrated benefits on progression-free survival (PFS) overall (OS) is a standard of care for the advanced V600-mutant melanoma. Here, we report 5-year update from COLUMBUS trial (ClinicalTrials.gov identifier: NCT01909453).Patients locally unresectable or metastatic melanoma, untreated progressed after first-line immunotherapy, were randomly assigned 1:1:1 to encorafenib 450 mg once daily plus binimetinib 45 twice daily, vemurafenib...
Nivolumab and relatlimab activity in advanced melanoma with prior progression on anti-programmed death-1/programmed death ligand 1 (PD-(L)1)-containing regimens is under investigation. RELATIVITY-047 demonstrated significantly improved progression-free survival (PFS) for nivolumab over previously untreated melanoma.The phase I/IIa, open-label RELATIVITY-020 trial part D assessed efficacy safety of during, or within 3 months of, (D1) ≥ (D2) anti-PD-(L)1-containing regimens. Safety was a...
The recurrence rates of Hepatocellular carcinoma (HCC) are high, necessitating novel and effective adjuvant therapies. Therefore, we conducted a phase II study glypican-3 (GPC3) peptide vaccine as an therapy for HCC patients. Forty-one patients with initial who had undergone surgery or radiofrequency ablation (RFA) were analyzed in this II, open-label, single-arm trial. Ten vaccinations performed 1 y after curative treatment. We also investigated case-control subjects, where selected treated...
An anti-programmed cell death protein 1 monoclonal antibody, nivolumab, is one of the most effective drugs for advanced melanoma. Tumor cell-derived or immune markers and clinical predictors such as serum lactate dehydrogenase (LDH) cutaneous adverse events, have already been described prognostic factors melanoma treated with nivolumab. We sought to identify further that can be determined in routine practice.We retrospectively analyzed findings 98 consecutive patients unresectable stage III...
Thyroid dysfunction (TD) induced by immune checkpoint inhibitors is not sufficiently understood. The purpose of this retrospective observational study was to identify risk factors and the clinical course TD nivolumab. Patients with advanced solid tumors who were treated nivolumab from March 2009 through 2016 at National Cancer Center Hospital (Tokyo, Japan) included. function antithyroid Abs serum samples among all patients evaluated baseline during treatment. Overt hypothyroidism defined as...
Promising antitumor activities of nivolumab, a fully humanized IgG4 inhibitor antibody against the programmed death-1 protein, were suggested in previous phase 1 studies. The present 2, single-arm study (JAPIC-CTI #111681) evaluated nivolumab and explored its predictive correlates advanced melanoma patients at 11 sites Japan. Intravenous 2 mg/kg was given repeatedly 3-week intervals to 35 37 enrolled from December 2011 May 2012 until they experienced unacceptable toxicity, disease...
Metastatic and chemoresistant melanoma can be a good target of immunotherapy because it is an intractable cancer with very poor prognosis. Previously, we tested dendritic cell (DC)-based phase I vaccine, confirmed that was safe. In the present study, performed II trial DC vaccine for metastatic patients mainly HLA-A24 genotype, investigated efficacy vaccine. Twenty-four were enrolled into study DC-based immunotherapy. The group included 19 HLA-A24-positive (A*2402) 3 HLA-A2-positive (A*0201)...
Interstitial lung disease (ILD) occurrence and risk factors were investigated in the Japanese non-small-cell cancer, post-marketing, large-scale surveillance study, POLARSTAR. All patients with unresectable, recurrent/advanced cancer who treated erlotinib Japan between December 2007 October 2009 enrolled. Primary endpoints patterns of ILD for onset ILD-related death. Overall survival, progression-free adverse drug reactions secondary endpoints. was confirmed 429 (4.3%) patients....